natgillin/translations-raw huggingface dataset:
The method of claim 1, wherein the cancer is selected from the group consisting of lung carcinoma, pancreatic carcinoma, bladder carcinoma, colon carcinoma, myeloid disorders, prostate cancer, thyroid cancer, melanoma, adenomas and carcinomas of the ovary, eye, liver, biliary tract, and nervous system. The method of claim 2, wherein the cancer is melanoma. The method of claim 3, wherein the cancer is metastatic melanoma. 
Spoj za uporabu u postupku liječenja prema zahtjevu 11 ili uporaba prema zahtjevu 12, naznačen/a time, da je rak koji se treba liječiti odabran iz skupine koju čine: karcinom pluća, karcinnom pankreasa, karcinom mjehura, karcinom debelog crijeva, mijeloidni poremećaji, rak prostate, rak štitnjače, melanom, adenomi i karcinomi jajnika, oka, jetre, žučnog trakta i nervnog sustava.
(*) amount sufficient to provide to the sugar replacement composition a sweetness about equal to the sweetness of sugar. 
* (*) Količina dovoljna da sastavina koja zamjenjuje šećer ima približno jednaku slatkoću kao 1 šećer.
A method for making the crystalline form in accordance with claim 2, said method comprising the following steps: 
Postupak za izradu kristaliničnog oblika u skladu sa zahtjevom 1 ili 2, naznačen time, da navedeni postupak sadrži slijedeće korake:
A pharmaceutical composition comprising the compound of claim 6, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients. 
7. < Farmaceutska kompozicija koja sadrži spoj iz zahtjeva 6, ili njegovu farmaceutski prihvatljivu sol, i jednu ili više 15 farmaceutski prihvatljivih pomoćnih tvari.
wherein at least 50% of said compound is present in the form of the sodium salt compound according to claim 2, 3 or 4 . 
(1 pri čemu najmanje 50% od toga spoja je prisutno u obliku natrijeve soli od spoja prema zahtjevu 1, 2, 3, 4, 5, 6111 7.
applying a liquid lacquer onto at least part of the outer surface of the metal casing of the gas purging plug and forming a liquid lacquer coat thereon, 
nanošenje tekućeg laka barem na dio vanjske površine (12p) metalne navlake (12) od pročišćivača za plin i oblikovanje tekućeg lakiranog premaza na njoj;
is allowed to react with hydrogen in the presence of a 5% palladium/1% iron catalyst on carbon which is water-wetted, in suspension in a solvent, such as methanol for example, thereby providing a compound of formula (5). 
O. (4) ' ostavljen da reagira s vodikom u prisutnosti 5% paladijevog/1% željezovog katalizatora na ugljiku koji je navlažen vodom, u otapalu, čime se dobiva spoj s formulom (5).
The method according to claim 8, further comprising affixing at least one coating layer (14) to said substrate (12); and providing said pattern (15) on said coating layer (14). 
Metoda iz zahtjeva 8, koja još uključujuće pričvršćivanje najmanje jedne obloge (14) za navedenu podlogu (12) te ugrađivanje navedenog uzorka (15) na navedenu oblogu (14).
The method according to claim 13 or 14, wherein the component to be replaced is an object made from a ferritic-austenitic steel alloy having an elementary composition as defined in any one of the claims 1, 4, or 5, and subjected to a processing technique selected from the group consisting of machining, drilling and combinations thereof. 
Metoda prema zahtjevu 13 ili 14, pri čemu komponenta koja se zamjenjuje dolazi kao predmet dobiven iz feritno-austenitne čelične legure s elementarnim sastavom definiranim u zahtjevu 1, 4 ili 5 i podvrgnut strojnoj obradi ili bušenju ili kombinaciji ove dvije tehnike.
A process for preparing Compound 21: comprising: 
Postupak dobivanja Spoja 21: N X
titrating the supernatant under neutral conditions and adding NaCl to make a final concentration of the solution to 2.6M NaCl; 
titracije supernatanta pod neutralnim uvjetima i dodavanja NaCl da se dobije konačna koncentracija otopine od 2.6M NaCl;
The process of claim 12, characterized by at least one of the following features: 
Postupak prema paleninom zahljevu 12, naznačen najmanje jednom od slijedećih karakteristika:
A composition according to claim 1, which further contains a co-herbicide selected from the group consisiting of aryloxy- and heteroaryloxyphenoxy propionic acids, cyclohexanediones cyclohexandiones, sulfonyl ureas, triazolopyrimidines, nitriles, thiocarbamates, dinitroanilines, benzoic acids, phenoxy acids and pyridine carboxylic acids. 
Pripravak prema zahtjevu 1 naznačen time da sadrži ko-herbicide odabrane iz skupine koja obuhvaća ariloksi- i heteroariloksifenoksi propionske kiseline, cikloheksandione, sulfonil uree, triazolopirimidine, nitrile, tiokarbamate, dinitroaniline, benzojeve kiseline, fenoksi kiseline i piridin karboksilne kiseline.
Process for producing high density polyethylene composition having high environmental stress crack resistance from post consumer plastic and articles made of said composition 
POSTUPAK IZRADE POLIETILENA VISOKE GUSTOĆE, OTPORNOG NA PUKNUĆA ZBOG VISOKIH OKOLIŠNIH PRITISAKA, OD OTPADA KOJI STVARAJU POTROŠAČI (POST CONSUMER RESIN, PCR) I PREDMETA IZRAĐENIH OD SPOMENUTOG SASTAVA
directing the feedstock stream to a first reaction zone where it is contacted with a metal carbonyl compound and where at least a portion of the ethylene oxide is converted to a product stream comprising beta propiolactone; 
usmjeravanja struje sirovine u prvo područje reakcije gdje dolazi u kontakt s metalnim karbonilnim spojem i gdje se u najmanju ruku dio etilen-oksida prevede u struju produkta koja sadrži B-propiolakton;
The antibody of any one of paras 1-3, wherein the antibody comprises: a) a heavy chain comprising a HVR-H1 comprising the amino acid sequence of SEQ ID NO:49, HVR-H2 comprising the amino acid sequence of SEQ ID NO:73, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:97; and/or b) a light chain comprising a HVR-L1 comprising the amino acid sequence of SEQ ID NO:13, HVR-L2 comprising the amino acid sequence of SEQ ID NO:25, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:37. 
ili (D HR P20180352 T1 teški lanac koji obuhvaća HVR-HI koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 49, HVR-H2 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 73, i HVR-H3 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 97, te laki lanac koji obuhvaća HVR-L1 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 13, HVR-L2 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 25, i HVR-L3 koje sadrži aminokiselinsku sekvencu od SEQ ID NO: 37.
After stirring at room temperature for 15 minutes, the reaction mixture was diluted with ethyl acetate, washed with saturated NaHCO3 solution and brine. 
Nakon miješanja na sobnoj temperaturu tijekom 15 minuta, reakcijska smjesa se razrijedi etil acetatom, ispere zasićenom otopinom NaHCO, i otopinom soli.
A compound for use of Claim 24 wherein the therapy is the treatment or prevention of nasal congestion, pulmonary congestion or asthma. 
Spoj za uporabu prema patentnom zahtjevu 24 naznačen time što je terapija tretman ili prevencija nazalne kongestije, plućne kongestije ili astme.
The agent for use according to claim 4, wherein the agent is for treating pulmonary fibrosis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je sredstvo za liječenje plućne fibroze.
1a the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof, and wherein said proteasome inhibitor is bortezomib. 
1a [image] njegove farmaceutski prihvatljive kisele i bazne adicione soli i stereokemijski izomerni oblici, te pri čemu je navedeni inhibitor proteasoma, bortezomib.
In practice, said waterproof inshoe 227 is constituted by a base insole 229, in which the peripheral edge 230 completely overlaps the connecting region 217 between the insole 216 and the breathable and waterproof membrane 215, so as to provide a peripheral seal formed by a sealing area 227a. 
U praksi, navedenu vodootpornu unutarnju cipelu 227 tvore osnovni unutarnji potplat 229, čiji se rubni dio 230 u potpunosti preklapa preko spojnog područja 217 između unutarnjeg potplata 216 i prozračne i vodootporne membrane 215, tako da područje zatvaranja 2274 tvori periferni hermetički spoj.
The pharmaceutical composition according to claim 24, wherein the disease associated with uric acid is hyperlipidemia, ischemic heart disease, myocardial infarction, cerebral infarction, cerebrovascular disease, diabetes or hypertension. 
Farmaceutski pripravak prema zahtjevu 24, gdje bolest povezana s mokraćnom kiselinom jest hiperlipidemija, ishemična bolest srca, infarkt miokarda, cerebralni infarkt, cerebrovaskularna bolest, dijabetes ili hipertenzija.
is selected from the group of alkyl, substituted alkyl, COOR29, COONR30R31. 
R>s je izabran iz grupe koju čine alkil, supstituirani alkil, COOR>»9, COONR3R31.
A is selected from the group consisting of 
A se bira iz skupine koju čine
There is thus provided as a further aspect of the invention a compound of formula (I) or a physiologically acceptable solvate thereof for use in human or veterinary medicine, particularly in the treatment of patients with inflammatory and/or allergic conditions. 
Spoj formule (1), ili njegov fiziološki prihvatljiv solvat, namijenjen upotrebi u liječenju pacijenata u skladu s patentnim zahtjevom 5, naznačen time što upalno i/ili alergijsko stanje je astma.
Apparatus for treating water at low cost for use as raw material in at least one downstream industrial process, which eliminates suspended solids in the water by filtering a small fraction of the total volume of water, the apparatus comprising: 
Metoda za tretiranje vode niskih troškova te za korištenje nizvodno od industrijskog postupka (2), koja pročišćava vodu i uklanja otopljene čvrste čestice u vodi filtriranjem male frakcije ukupnog volumena vode, metoda obuhvaća:
The lysine residue at position 860 of SEQ ID NO: 1, 7, 8 or at position 859 of SEQ ID NO:9 has been substituted by a conservative amino acid residue. 
(1) zamjeni ostatka glutaminske kiseline, koji odgovara položaju 570 u sekvenci nativnog CyaA u Bordetella pertussis kako je definirano u SEQ ID NO:1, glutaminom;
The use according to claim 6, wherein said carotenoid is chosen from crocetin, a-crocin (S,S-diapo-S,S-carotenoic acid), zeaxanthine, lycopene, a-carotene, B-carotene, bixin, and fucoxanthine, or wherein said carotenoid is present in the composition as a mixture chosen from saffron red powder, annatto extract and brown algae extract. 
Upotreba u skladu s patentnim zahtjevom 6, naznačena time što se navedeni karotenoid bira između krocetina, a-krocina (S,S-diapo-S,S-karotenske kiseline), zeaksantina, likopena, a-karotena, B-karotena, biksina, te fukoksantina, ili gdje je navedeni karotenoid prisutan u pripravku u obliku smjese koju se bira između crvenog praha iz šafrana, ekstrakta anata i ekstrakta smeđih algi.
The pure compactin was then fermented into pravastatin and isolated according to the methods disclosed in U.S. Patent No. 6,444,452 . 
Čisti je kompaktin zatim fermentiran u pravastatin i izoliran prema postupcima opisanima u U.S. Patentu 6,444,452.
• 5-Lipoxygenase (5-LO) inhibitors or 5-lipoxygenase activating protein (FLAP) antagonists 
5-lipoksigenaza (5LO)-inhibitori ili antagonisti aktivacije proteina 5-lipoksigenaze (FLAP-antagonisti),
Atomiser according to claims 8 and 12, characterised in that the control part (45) can be operated or moved by the rider (49), in particular parallel to the axis, in order to achieve a blocking of the atomiser (1) or a locked state. 
Raspršivač prema zahtjevima 8 1 12, naznačen time, da upravljač (45) može raditi ili se pokretati pomoću pokretnog utega (49), posebno paralelno na os, kako bi postigao zaustavljanje raspršivača (1) ili kako bi postigao zatvoreno stanje.
comparing the level of cell death-stable enzyme activity (X) in the portion of the cell culture medium containing cells of the tissue-engineered product to the level of cell death-stable enzyme activity (Y) in the portion of the cell culture conditioned medium not containing cells of the tissue-engineered product, 
(e) usporedbe razine enzimske aktivnosti stabilne stanične smrti (X) u dijelu medija stanične kulture koji sadrži stanice produkta preinačenog-tkiva prema razini enzimske aktivnosti stabilne stanične smrti (Y) u dijelu kondicioniranog medija stanične kulture koji ne sadržava stanice produkta preinačenog-tkiva, pri čemu je citotoksičnost tretmana proporcionalna prema razlici u udjelu vijabilnih stanica u obrađenom produktu preinačenog-tkiva prema neobrađenom produktu premačenog-tkiva, te pri čemu se udio vijabilnih stanica u produktu preinačenog-tkiva može izračunati prema formuli:
Also described is a medicament delivery device containing a composition described herein, said device adapted to deliver individual or successive doses of said composition, each individual or successive dose having a volume of less than 1000 microlitres. 
Uređaj za primjenu lijeka naznačen time što sadrži kompoziciju prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je navedeni uređaj prilagođen za primjenu pojedinačnih ili uzastopnih doza navedene kompozicije, pri čemu svaka pojedinačna 1li uzastopna doza ima volumenu manji od 1000 mikrolitara.
The method of claim 1, wherein gas from the aroma fraction remaining after step d) is subjected to one or more further condensation steps to produce one or more further aroma fractions. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se plin iz aromatične frakcije koja preostane nakon koraka c) podvrgava jednom ili više dodatnih koraka kondenziranja kako bi se proizvelo jednu ili više aromatičnih frakcija.
A dosage form according to claim 9, wherein component (c) is at least one opiate or opioid antagonist selected from the group consisting of naloxone, naltrexone, nalmefene, nalid, nalmexone, nalorphine, naluphine and a corresponding physiologically acceptable compound. A dosage form according to claim 9, wherein component (c) is at least one neuroleptic stimulant antagonist. 
Oblik davanja lijeka prema patentnom zahtjevu 10 ili 11, naznačen time, da je komponenta (c) barem jedan opioid- antagonist izabran iz skupine koja obuhvaća naloxon, naltrexon, nalmefen, nalid, nalmexon, nalorphin, naluphin i odgovarajući fiziološki podnošljivi spoj, osobito baza, sol ili solvat.
The process of item 18, wherein the temperature profile during the curing step shows a plateau-like form and wherein said temperature is preferably at least about 68 °C and the curing time is preferably in the range of from about 1 minute to about 2 hours. 
Postupak prema zahtjevu 18, naznačen time da temperaturni profil u toku koraka stvrdnjavanja pokazuje oblik platoa i gdje je navedena temperatura barem oko 68 "C i gdje je vrijeme stvrdnjavanja poželjno u rasponu od oko 1 minute do oko 2 sata.
The device (1) for overturning containers (2) according to claim 1, wherein the rotation actuator (3) is a rack and pinion type actuator. 
Uređaj (1) za okretanje spremnika (2) u skladu s bilo kojim zahtjevom od 1 do 2, naznačen time da je rotacijski pokretač (3) pogonjen putem zupčanika i nazubljene letve.
a C3-8 cycloalkyl group optionally substituted by the same or different 1 to 5 substituents selected from the following group B, 
-8 cikloalkil skupina, opcijski supstituirana sa 1 do 5 istih ili različitih supstituenta izabranih iz slijedeće skupine B,
The host cell of paragraph 57 wherein the host cell is a gram negative bacterium. 
Stanica domaćin u skladu s patentnim zahtjevom 21, naznačena time što je stanica domaćin gram negativna bakterija.
The oral solid pharmaceutical composition according to any of the preceding claims, wherein the one or more binder(s) are selected from the group comprising of hydroxypropyl methylcellulose (HPMC), dihydroxy propyl cellulose, methyl cellulose, hydroxyethyl cellulose, ethyl cellulose, sodium carboxyl methylcellulose, polyethylene glycol, maltodextrin, pregelatinized starch, starch, polymethacrylates, sodium alginate, polyvinylpyrrolidone (povidone) and vinylpyrrolidone/ vinylacetate copolymer (copovidone). 
Oralni kruti farmaceutski sastav prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da su jedno ili više veziva izabrani iz skupine koja obuhvaća hidroksipropilmetilcelulozu (HPMC), dihidroksipropilcelulozu, metilcelulozu, hidroksietilcelulozu, etilcelulozu, natrijkarboksimetilcelulozu, polietilenglikol, maltodekstrin, predželatinirani škrob, škrob, polimetakrilate, natrijev alginat, polivinilpirolidon (povidon) i kopolimer vinilpirolidona/vinilacetata (kopovidon).
Chromatographic systems having a hydrophobic stationary phase have also been widely employed in the purification of proteins. 
Kromatografski sustavi koji posjeduju hidrofobnu stacionarnu fazu također su u širokoj uporabi u pročišćavanju proteina.
30 or a sequence having at least 80 % sequence identity with SEQ ID Nos. 
3 (RRDFPEEVAIAEELG) ili sekvencu sa najmanje 80% identiteta sekvence sa SEQ ID No.
sequentially associating the sequentially extracted first-type syntax elements to the positions of the transform coefficient block in a predetermined scan order among the positions of the transform coefficient block, 
Postupak za kodiranje signifikacijske mape u protok podataka, koja prikazuje pozicije signifikantnih koeficijenata transformacije unutar bloka koeficijenata transformacije, naznačen time, da taj postupak obuhvaća sljedeće:
Splitting of the nails is rarely caused by internal disease or vitamin deficiency, nail polish remover causes onychoschizia (lamellar splitting), finally trauma to the fingers contributes to onychoschizia. 
Cijepanje noktiju je rijetko uzrokovano unutarnjom bolesti ili nedostatkom vitamina, odstranjivač laka za nokte uzrokuje listanje noktiju (lamelarno cijepanje), te napokon ozljeda prstiju doprinosi listanju noktiju.
The apparatus of claim 10, wherein the L1 signaling data includes notch width information indicating a width of a notch band existing in the signal frame. 
Uređaj iza patentnog zahtjeva 10, pri čemu signalni podatak LI uključuje informaciju širine obilježja koja ukazuje širinu polja obilježja koje postoji u okviru signala,
In a corresponding way, the invention relates also to a method for decoding a data signal representative of at least one image split to partitions which has been previously encoded, comprising a step for obtaining, by the entropy decoding of data of the signal, digital information items associated with residual data items relating to at least one previously encoded partition. Such a decoding method is notable in that it comprises the following steps: 
Postupak dekodiranja signala podataka (F) koji predstavlja barem jednu sliku podijeljenu u particije koja je bila prethodno kodirana, koji sadrži korak dobivanja (D2), pomoću entropijskog dekodiranja stavki podataka za navedeni signal, digitalnih informacija povezanih sa preostalim stavkama podataka koje se odnose na barem jednu prethodno kodiranu particiju, te je skup preostalih stavki podataka postavljen u blok preostalih stavki podataka, te je navedeni postupak dekodiranja naznačen time da sadrži slijedeće korake:
As shown in Table 3, the extent of hydrolysis in human whole blood varied greatly depending on the nature of the carbohydrate moiety. 
Kako je prikazano u Tablici 3, stupanj hidrolize u punoj ljudskoj krvi znatno varira, ovisno o prirodi ugljikohidratne jedinice.
preparing a clear and homogeneous solution of the two or more polymers and the at least one lipophilic active compound in a mixture of water and an organic solvent; and drying the polymers-lipophilic active compound complex clear and homogeneous solution of (i) to form a dry powder; wherein the aqueous solution has at least 50% by weight of water and the drying in step (ii) is carried out by spray drying. 
(i) pripremanje bistre i homogene otopine dva ili više polimera i najmanje jednog lipofilnog aktivnog spoja u smjesi vode i organskog otapala; i (ii) sušenje bistre i homogene otopine polimera-lipofilnog aktivnog spoja (1) za formiranje suhog praha; pri čemu vodenasta otopina ima najmanje 50% težinski vode i sušenje u koraku (ii) se provodi sušenjem raspršivanjem.
A compound of any preceding claim, wherein R1 is a substituted or unsubstituted heterocyclic moiety which either contains 6 atoms in a single ring or 10 atoms in a fused bicyclic ring system, optionally wherein R1 is selected from substituted or unsubstituted: pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl, tetrahydroquinolinyl, dihydroquinolinyl, quinolinone-yl, tetrahydroquinolinone-yl, dihydroquinolinone-yl, isoquinolinyl, tetrahydroisoquinolinyl, dihydroisoquinolinyl, isoquinolinone-yl, tetrahydroisoquinolinone-yl, dihydroisoquinolinone-yl, napthyridinyl, oxo-napthyridinyl, dihydronappthyridinyl, tetrahydronaphthyridinyl, oxo-tetrahydronaphthyridinyl, and oxo-dihydro-H-naphthyridinyl, further optionally wherein R1 is substituted or unsubstituted pyridyl or substituted or unsubstituted oxo-dihydro-H-naphthyridinyl. 
Spoj iz bilo kojeg prethodnog zahtjeva, pri čemu R1 predstavlja supstituiranu ili nesupstituiranu heterocikličku skupinu koja sadrži 6 atoma u jednom prstenu ili 10 atoma u sustavu kondenziranih bicikličkih prstena, pri čemu se R1 eventualno odabire iz supstituiranih ili nesupstituiranih: piridila, piridazinila, pirimidinila, pirazinila, kvinolinila, tetrahidrokvinolinila, dihidrokvinolinila, kvinolinonila, tetrahidrokvinolinonila, dihidrokvinolinonila, izokvinolinila, tetrahidroizokvinolinila, dihidroizokvinolinila, izokvinolinonila, tetrahidroizokvinolinonila, dihidroizokvinolinonila, naftiridinla, okso-naftiridinila, dihidronaftiridinila, tetrahidronaftiridinila, okso-tetrahidronaftiridinila, i okso-dihidro-H-naftiridinila, pri čemu R1 eventualno predstavlja supstituirani ili nesupstituirani piridil ili supstituirani ili nesupstituirani okso-dihidro-H-naftiridinil.
Preferably, the pack is generally U-shaped having a core extended by the two walls, the bottle and the juice it contains preferably being visible on at least two opposite sides of the core. 
Proizvod (10) u skladu s barem jednim od prethodnih patentnih zahtjeva, naznačen time, da je bočica (12) vidljiva na najmanje dvije suprotne strane pakiranja (14).
The present invention now resolves these deficiencies. In a first aspect, the invention relates to a container for storing and unloading bulk material comprising: 
Spremnik (1) za skladištenje i istovar rasutog materijala koji sadrži posudu (2) sa zatvorenim (3) i otvorenim krajem (4), naznačen time što sadrži:
The method according to claim 1, wherein the disease or disorder is prostate cancer. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak prostate.
System according to claim 5, wherein the mobile chains are constrained to a support (18), which slides along lateral guides of the module and is driven by a linear motor (19), until the engaged frame is brought into the desired position to create the aforesaid aisle. 
Sustav u skladu s patentnim zahtjevom 2, naznačen time što su mobilni lanci učvršćeni na nosač (18) koji kliže duž bočnih vodilica modula i održava se u pogonu pomoću linearnog motora (19), sve dok se zahvaćeni okvir ne dovede u željeni položaj kako bi se stvorio prije navedeni prolaz.
A method according to claim 8 wherein said carrier is a liposomal solution or an oil in water emulsion. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je navedena podloga liposomska otopina ili emulzija ulja u vodi.
The Compound of Claim 3 where R6 is phenyl optionally substituted with 1, 2, or 3 R9 groups; or a single stereoisomer or mixture of stereoisomers thereof and optionally as a pharmaceutically acceptable salt or solvate thereof. 
Spoj prema patentnom zahtjevu 3, naznačen time što je R6 jednako fenil izborno supstituiran sa 1, 2 ili 3 R9 grupe; ili njegov pojedinačni stereoizomer ili smjesa stereoizomera i izborno kao njegova farmaceutski prihvatljiva sol ili solvat.
A compound as defined in any preceding claims wherein R2 represents a 5 membered heterocyclyl group optionally substituted by one or more Ra groups. 
Spoj prema bilo kom od prethodnih zahtijeva, pri čemu R2 predstavlja 5-članu heterociklil grupu opcionalno supstituiranu sa jednom ili više Ra grupa.